Is Mylan The New Valeant?
Mylan NV CEO Heather Bresch is the new face of pharmaceutical price gouging. Her company is being targeted for hiking the price of a lifesaving anti-allergy injection called EpiPen by more than 500% to some $600 since acquiring it in 2007. Right alongside the price hike, Ms. Bresch’s compensation has gone up from $2.5 million in 2007 to nearly $19 million in 2015.